Rho kinase inhibitor vs placeboa
Average number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
- Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 188 participantsVery low